Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 232Lymphoma 46Lymphoma, Mantle-Cell 44Neoplasms, Plasma Cell 40Recurrence 30Lymphoma, Non-Hodgkin 29Lymphoma, Follicular 26Leukemia, Myeloid, Acute 25Lymphoma, Large B-Cell, Diffuse 22Waldenstrom Macroglobulinemia 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Lymphoma, B-Cell, Marginal Zone 19Leukemia, Lymphocytic, Chronic, B-Cell 19Carcinoma, Non-Small-Cell Lung 18Leukemia 15Hodgkin Disease 13Neoplasms 12Immunoglobulin Light-chain Amyloidosis 12Hematologic Neoplasms 11Unspecified Adult Solid Tumor, Protocol Specific 9Myelodysplastic Syndromes 9Lymphoma, B-Cell 9Burkitt Lymphoma 9Lymphoma, Large-Cell, Immunoblastic 8Lymphoma, Large-Cell, Anaplastic 8Head and Neck Neoplasms 8Congenital Abnormalities 8Breast Neoplasms 8Sarcoma 7Lymphoma, Extranodal NK-T-Cell 7

Interventions

mogamulizumab 4Lenalidomide 3Cyclophosphamide 3Alemtuzumab 2peginterferon alfa-2b 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1cobomarsen 1belinostat 1Zidovudine 1Vincristine 1Raltegravir Potassium 1Prednisone 1Oxaliplatin 1Introns 1Interleukin-15 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Etoposide 1Doxorubicin 1Dexamethasone 1Daclizumab 1Cytarabine 1Cisplatin 1Calcium Dobesilate 1Bortezomib 1B3(Fv)-PE38KDEL recombinant immunotoxin 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia-Lymphoma, Adult T-Cell × Bortezomib × Clear all
NCT01000285 2017-03-28

ATLL

Washington University School of Medicine

Phase 1/2 Completed
18 enrolled 13 charts
LymphoidOther hematologic neoplasm

Leukemia-Lymphoma, Adult T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡